BioAtla, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-18$61.00 RISE2026-02-18$7.05 PEAK2026-02-27$12.35 101d | -88.4% 92d | Missed | Missed | — | — | +75.2% 9d | Missed |
DROP2025-11-18$61.00 RISE2026-02-17$7.05 PEAK2026-02-27$12.35 101d | -88.4% 91d | Missed | Missed | — | — | +75.2% 10d | Missed |
DROP2025-05-02$27.90 RISE2025-08-01$16.50 PEAK2025-10-09$51.00 160d | -40.9% 91d | Missed | Missed | — | — | +209.1% 69d | Missed |
DROP2025-05-02$27.90 RISE2025-05-27$19.05 PEAK2025-06-03$26.15 32d | -31.7% 25d | Missed | Missed | — | — | +37.3% 7d | Missed |
DROP2024-11-29$84.00 RISE2025-04-08$13.35 PEAK2025-05-02$27.90 154d | -84.1% 130d | Missed | Missed | — | — | +109.0% 24d | Missed |
DROP2024-11-11$118.50 RISE2025-03-03$15.25 PEAK2025-05-02$27.90 172d | -87.1% 112d | Missed | Missed | — | — | +83.0% 60d | Missed |
DROP2024-05-16$155.00 RISE2024-09-25$80.75 PEAK2024-11-11$118.50 179d | -47.9% 132d | Missed | Missed | — | — | +46.7% 47d | Missed |
DROP2024-04-04$196.00 RISE2024-08-12$69.50 PEAK2024-10-03$117.50 182d | -64.5% 130d | Missed | Missed | — | — | +69.1% 52d | Missed |
DROP2024-04-04$196.00 RISE2024-08-07$69.50 PEAK2024-10-03$117.50 182d | -64.5% 125d | Missed | Missed | — | — | +69.1% 57d | Missed |
DROP2024-04-04$196.00 RISE2024-07-09$58.50 PEAK2024-07-16$102.50 103d | -70.2% 96d | Missed | Missed | — | — | +75.2% 7d | Missed |
DROP2024-04-04$196.00 RISE2024-04-19$105.25 PEAK2024-05-01$168.50 27d | -46.3% 15d | Missed | Missed | — | — | +60.1% 12d | Missed |
DROP2023-12-27$159.00 RISE2024-02-01$94.00 PEAK2024-04-04$196.00 99d | -40.9% 36d | Missed | Missed | — | — | +108.5% 63d | Missed |
DROP2023-08-03$150.00 RISE2023-12-04$68.50 PEAK2023-12-27$159.00 146d | -54.3% 123d | Missed | Missed | — | — | +132.1% 23d | Missed |
DROP2023-06-21$191.00 RISE2023-10-27$63.50 PEAK2023-12-27$159.00 189d | -66.8% 128d | Missed | Missed | — | — | +150.4% 61d | Missed |
DROP2023-02-03$213.50 RISE2023-05-25$150.00 PEAK2023-06-20$192.00 137d | -29.7% 111d | Missed | Missed | — | — | +28.0% 26d | Missed |
1–15 / 20 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Context Therapeutics: Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 Context Therapeutics announces buyout of CT-202 future milestones and royalties ...
Phase 1 initiation for CT-202 trial expected in third quarter of 2026
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.30) by 47.19 percent. This is a 46.67 percent increase over losses of $(0.30) per share from the same
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Shares of Smith & Wesson Brands Inc (NASDAQ:SWBI) rose sharply in pre-market trading after the company reported better-than-expected third-quarter
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BCAB | -7.96% | -61.47% | -86.16% | -80.78% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -10.93% | -55.76% | -82.72% | -93.47% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 510.5K | $82.19K | 0.00% | Trimmed-27.8% | 2026-03-31 |
| StateStreet | passive | 151.4K | $24.37K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -8.50 | — | — |
| 2025-11-13 | -14.83 | -13.50 | +8.99% |
| 2025-08-07 | -14.67 | -16.00 | -9.09% |
| 2025-05-06 | -14.67 | -13.00 | +11.36% |
| 2025-03-28 | -19.00 | -15.00 | +21.05% |
| 2024-11-07 | -18.50 | -11.00 | +40.54% |
| 2024-08-08 | -23.00 | -22.00 | +4.35% |
| 2024-05-14 | -27.12 | -24.00 | +11.52% |
| 2024-03-26 | -39.62 | -28.00 | +29.34% |
| 2023-11-07 | -39.87 | -35.00 | +12.23% |
| 2023-08-01 | -32.10 | -37.50 | -16.82% |
| 2023-05-11 | -31.20 | -29.00 | +7.05% |
| 2023-03-23 | -37.20 | -31.50 | +15.32% |
| 2022-11-04 | -40.80 | -34.50 | +15.44% |
| 2022-08-09 | -34.26 | -38.50 | -12.39% |
| 2022-05-05 | -31.50 | -32.50 | -3.17% |